Nauck, Michael A.
Müller, Timo D.
Funding for this research was provided by:
Universitätsklinikum der Ruhr-Universität Bochum
Article History
Received: 10 February 2023
Accepted: 4 May 2023
First Online: 11 July 2023
Acknowledgements
: We acknowledge help from Sonja Bartholomé in retrieving literature.
: Data extracted from included studies; data used for all analyses and any other materials used in the review can be accessed on reasonable request and at the discretion of the authors by contacting the corresponding author.
: Open Access funding enabled and organized by Projekt DEAL. Work in TDM’s laboratory is supported by the German Research Foundation (DFG TRR296, TRR152, SFB1123 and GRK 2816/1), the German Center for Diabetes Research (DZD) and the European Research Council ERC-CoG Trusted (no.101044445).
: MAN has been a member of the advisory boards of, or has consulted with, Boehringer Ingelheim, Eli Lilly, Medtronic, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Regor, Sun Pharma and Structure Therapeutics (ShouTi, Gasherbrum). He has received grant support from Merck Sharp & Dohme. He has also served on the speakers’ bureau of Eli Lilly, Menarini/Berlin Chemie, Merck Sharp & Dohme, Medscape, Medical Learning Institute and Novo Nordisk. TDM receives funding from Novo Nordisk and has received speaking fees within the last 3 years from Novo Nordisk, Eli Lilly, AstraZeneca and Berlin Chemie.
: MAN and TDM designed the review and jointly searched the literature, designed the figures and tables and wrote the manuscript. Both authors approved the final draft of the manuscript and the decision to submit it for publication. The manuscript is in part based on the content of MAN's Claude Bernard Lecture presented on 20 September 2022 at the EASD Annual Meeting in Stockholm, Sweden. MAN takes full responsibility for the work.